Skip to main content
PolicySpeak
← All files
HUH

Haukeland University Hospital

Other · Norway

2
positions filed
in the 326 files tracked
1
legislative file
of 326 tracked
0
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Track Haukeland in PolicySpeak: request access →

Work at Haukeland University Hospital? so we know who speaks for it.

Follow the file Haukeland University Hospital engages with

One email on Tuesdays when a new position is filed on this file, from Haukeland University Hospital or from anyone else on it. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

Haukeland University Hospital filed 2 positions between 12 Jan 2026 and 24 Mar 2026, across 1 of the 326 legislative files tracked here.

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 24 Mar 2026source

With respect to the proposed amendments in IVDR Article 5(5)(a), allowing health institutions to transfer in house manufactured blood bank test cells for blood typing and antibody screening, when justified by patient safety or public health, constitutes an important and well founded proposal.

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 12 Jan 2026source

We welcome the Commissions initiative to revise the EU rules for medical devices and in vitro diagnostics. The current proposal for revisions to the MDR/IVDR includes important amendments regarding in-house devices (Art. 5(5)). We strongly support that these revisions should be treated as a high priority for adoption.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Is this your organization?

Everything on this page comes from Haukeland University Hospital’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.